Antibodies for Licensing
Scientists at the Georg-August-University Göttingen generated many different monoclonal antibodies. We are looking for companies, who are interested in licensing these antibodies for selling them to industrial and scientific institutions or for developing advanced diagnostic tests and therapeutic solutions.
This unique collection comprises the listed clones:
Overview available clones for licensing page 1
| Name | Clones | Host | Reactivity | Isotype | Application | References |
|---|---|---|---|---|---|---|
| Complementfactor B / Ba | P21/15 | mouse | human | IgG2a/k | WB,E,IP | 1-3 |
| M20/6 | mouse | human | IgG1/k | WB,E,IP | 1-4 | |
| D22/3 | mouse | human | IgG2b/k | WB,F,E | 2-4 | |
| Complementfactor B / Bb | M13/12 | mouse | human | IgG1/k | WB,E,IP | 1-3 |
| Complementfactor D | D10/4 | mouse | human | IgG2a/k | WB,E | 1-3; 5 |
| I8/1 | mouse | human | IgG1/k | WB,E | 1-3; 5 | |
| Complementfactor H | C18/3 | mouse | human | IgG1/k | WB,E | 1-3 |
| L20/3 | mouse | human | Ig1/k | WB,E | 1-3 | |
| Complementfactor H (402-His variant) | 23F8 | mouse | hunman | lgG1/k | IB, ELISA | not yet published |
| Complementfactor H (402-Tyr variant) | 1H10 | mouse | human | lgG1/k | IB, ELISA | not yet published |
| Activated C3 (iC3b/C3dg) | I3/15 | mouse | human | Ig1/k | WB,E | 1-3; 6; 7 |
| C3a/C3a(desArg)/C3 | K13/16 | mouse | human | IgG1/k | WB,E,IP,FN | 2; 3; 8-16 |
| D17/1 | mouse | human | IgG1/k | WB,E | 2; 3; 8; 10; 14-16 | |
| C5a/C5a(desArg)/C5 | C17/5 | mouse | human | IgG1/k | WB,E | 2; 3; 8; 10: 14-16; 19 |
| G25/2 | mouse | human | IgG1/k | WB,E | 2; 3; 8; 10: 14-16; 19 |
Overview available clones for licensing page 2
| Name | Clones | Host | Reactivity | Isotype | Application | References |
|---|---|---|---|---|---|---|
| C3a/C3a(desArg) | Z22/8 | mouse | porcine | IgG2b/k | WB,E,IP,FN | 3; 17;18 |
| K5/9 | mouse | porcine | IgG1/k | WB, E,FN | 3; 17;18 | |
| C5a/C5a (desArg) | T13/9 | mouse | porcine | IgG1/k | WB,E,IP,FN | 3; 17;18 |
| Complementreceptor C5aR (CD88) | P12/1 | mouse | human | IgG1/k | WB, F, IH | 20 |
| S5/1 | mouse | human | IgG2a/k | WB, F, E, FN, IP, blocking | 20 | |
| W17/1 | mouse | human | IgG1/k | F,E | 20 | |
| R63 | mouse | rat | IgG1/k | F,IH | 21 | |
| Phospho-C5aR/CD88 (Ser-334) | 32G-1 | mouse | human | lgG1/k | WB, IF, E20 | 42 |
| Chemokine receptor CCR5 | R22/7 | mouse | human | IF, FC, WB | 22 | |
| T21/8 | mouse | human | IgG2a/k | IF, FC, WB, IP, E | 22 | |
| Phospho CCR5 (Ser-349) | E11/19 | mouse | human | IF, WB, E | 22 | |
| Phospho CCR5 (Ser-337) | V14/2 | mouse | human | I, WB, E | 22 | |
| Nonphospho-CCR5 (Ser 337) | RC-10 | mouse | human | IF, WB, E | 22 | |
| R22/7 | mouse | human | IF, FC,WB | 22 | ||
| Chemokine receptor CCR7 | 4B12 | rat | mouse | IgG2a | IP, F | 23; 24 |
| Complementreceptor C3aR | hC3aRZ8 (clone17) | mouse | human | IgG2b | F, IH | 25; 26 |
| hC3aRZ3 (clone76) | mouse | human | IgG2b | FI | 27;28 |
Overview available clones for licensing page 3
| Name | Clones | Host | Reactivity | Isotype | Application | References |
|---|---|---|---|---|---|---|
| 74 | mouse | rat | F, IH | 29 | ||
| IG4 | rat | mouse | IgG1/k | F, IH | 26 | |
| 14D4 | rat | mouse | IgG2a | F, IH | 26 | |
| Complementreceptor C5aR | 20/70 | rat | mouse | IgG2b | F, Blocking | 30;31;32 |
| 10/92 | rat | mouse | IgG2a | F, IH | 31 | |
| 8D6 | rat | human | IgG2a | F, IH, Blocking | not yet published | |
| 15C4 | rat | human | IgG2a | F, IH, Blocking | not yet publishhed | |
| Beta-arrestin1 and Beta-arrestin2 | 25G10 | mouse | human, rat,hamster beta-arrestin1 | IgG1/k | WB, IP | not yet published |
| 21B1 | mouse | human, rat, hamster beta-arrestin1 and beta-arrestin2 | Ig1/k | WB, IP | 44 | |
| Chemokine receptor CCR9 | 9B1 | rat | mouse | IgG2a/k | F | 33 |
| Interleukin 8 | SE2 | mouse | human | IgG2b/k | F, WB, IH | 34 |
| HC2 | mouse | human | IgG1/k | F, WB IH | 34 | |
| Complementfactor H | IH10 | mouse | human | IgG1/k | IB, ELISA | not yet published |
| 23F8 | mouse | human | IgG1/k | IB, ELISA | not yet published | |
| Beta2-adrenergic receptor | 13D6 | mouse | human | IgG1/k | IB, IP, IF, F | not yet published |
| R11E1 | mouse | human | IgG1/k | IB, IP, IF, F | 43 |
Overview available clones for licensing page 4
| Name | Clones | Host | Reactivity | Isotype | Application | References |
| PIWIL2 | 87/3 | mouse | human | lgM | IH, ELISA | not yet published |
| Pox Viruses | BCoV1/1 | mouse | bovine coronavirus; human coronavirus | lgG1 | E; IF; VN | 35 |
| FPXV-8F3 | mouse | Fowlpoxvirus, Turkeypoxvirus | IgG3/k | E, IF, IB, IP, IGEM, NVN | 36 | |
| FPXV-3D9 | mouse | Fowlpoxvirus, Turkeypoxvirus | IgG1 | E, IF, IB, IP, IGEM, NVN | 36;37 | |
| VACV-5B4 | mouse | All orthopoxviruses without ectomelia and monkeypox | IgG2a | E, IF, IB, IP, F, IGEM, VN | 38;39;40 | |
| VACV-5C7 | mouse | Monkeypoyvirus and other orthopoxviruses | IgG1 | E, IF, IB, IP, IGEM, NVN | 39 | |
| PPV-4D9 | mouse | All Parapoxviruses | IgM | E, IF, IB, IP, F, IGEM, VN | 41 | |
| CNPV-5A11 | mouse | Canarypox virus | IgG2a/k | E, IF, IB, IP, IGEM, NVN | 37 | |
| VACV-5B1 | mouse | All orthopoxviruses | IgG2a | E, IF, IB, IP, F, IGEM, NVN | 39 | |
| AP-Tag / Avitag | EF10 | mouse | human | IgG1/k | E, IF, F, FN | 45 |
| Nanobodies | ||||||
| Synthaxin 1a | stx1a-Nb2_K81 | alpaca | rat | heavy chain IgG | IF, IB, E | in preparation |
| SNAP25 | S25-G1-D10 | alpaca | rat | heavy chain IgG | IF, IB, E | in preparation |
E: ELISA; IF: Immunofluorescence; IB: Immunoblotting; IP: Immunoprecipitation; IGEM: Immunogold electron microscopy; IH: Immunohistochemistry; F: Flow cytometry; FN: Functional studies; NVN: not virus neutralizing; VN: virus neutralizing; WB: Western blotting
Reference List for monoclonal antibodies mAB
- Oppermann, M., Baumgarten, H., Brandt, E., Gottsleben, W., Kurts, C., and Götze, O. (1990) J. Immunol.Methods133, 181-1902.
- Oppermann, M., Kurts, C., Zierz, R., Quentin, E., Weber, M. H., and Götze, O. (1991) Kidney Int.40, 939-947.
- Oppermann, M., Höpken, U., and Götze, O. (1992) Immunopharm.24, 119-134
- Oppermann, M. and Götze, O. (1994) Mol. Immunol.31, 307-314
- Kaiser, J., Oppermann, M., Götze, O., Deppisch, R., Göhl, H., Asmus, G., Röhrich, B., von Herrath, D., and Schäfer, K. (1994) Significant reduction of factor D and immunosuppressive complement fragment Ba by haemofiltration.
- Würzner, R., Schuff-Werner, P., Franzke, A., Nitze, R.,Oppermann, M., Armstrong, V. W., Eisenhauer, T., Seidel, D., and Götze, O. (1991) Eur. J. Clin. Invest.21, 288-294.
- Schuff-Werner, P., Schütz, E., Reitemeyer, F., Oppermann, M., Eisenhauer, T., Armstrong, V., Köstering, H., Götze, O., and Seidel, D. (1990) Heparin-induced extracorporeal LDL-precipitation (HELP): rheological, hemostaseological and immunological effects. In Gotto, A. M., Mancini, M., Richter, W. O., and Schwandt, P., editors. Treatment of severe hypercholesterolemia in the prevention of coronary heart disease, Basel, Karger
- Oppermann, M., Haubitz, M., Quentin, E., and Götze, O. (1988) Klin. Wochenschr.66, 857-864
- Püschel, G. P., Oppermann, M., Muschol, W., Götze, O., and Jungermann, K. (1989) FEBS Lett.243, 83-87
- Nezlin, R., Freywald, A., and Oppermann, M. (1993) Mol. Immunol.30, 935-940
- Püschel, G. P., Hespeling, U., Oppermann, M., and Dieter, P. (1993) Hepatology18, 1516-1521
- Elsner, J., Oppermann, M., Czech, W., Dobos, G., Schöpf, E., Norgauer, J., and Kapp, A. (1994) C3a activates oxygen radical species production and intracellular calcium transients in human eosinophils.
- Elsner, J., Oppermann, M., Czech, W., Schöpf, E., and Kapp, A. (1994) Blood83, 3324-3331.
- Ammon, H. P. T., Ege, W., Oppermann, M., Göpel, W., and Eisele, S. (1995) Anal. Chem.67, 466-471
- Püschel, G. P., Dieter, P., Muschol, W., Oppermann, M., Hülsmann, M., Schulze-Specking, A., Götze, O., Decker, K., and Jungermann, K. (1991) Prostanoid production in Kupffer cells: A step in the increase in glucose and lactate output and reduction of flow by anaphylatoxins in perfused rat liver. In Wisse, E., Knook, D. L., and Decker, K., editors. Cells of the hepatic sinusoid, Leiden, Kupffer Cell Foundation
- Lhotta, K., Würzner, R., Kronenberg, F., Oppermann, M., and Konig, P. (1998) Kidney Int.53, 1044-1051
- Höpken, U., Strüber, A., Oppermann, M., Mohr, M., Mücke, K. H., Burchardi, H., and Götze, O. (1993), Production and characterization of peptide-specific monoclonal antibodies that recognize a neoepitope on hog C5a. In Faist, E., Meakins, J., and Schildberg, F. W., editors. Host defense dysfunction in trauma, shock and sepsis, Berlin, Heidelberg, Springer Verlag.
- Höpken, U., Mohr, M., Struber, A., Montz, H., Burchardi, H., Götze, O., and Oppermann, M. (1996) Eur. J. Immunol.26, 1103-1109
- Oppermann, M., Schulze, M., Götze, O. (1991) A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArg) anaphylatoxin using monoclonal antibody with specificity for a neotope. Complement Inflamm. 8 (1):13-24
- Oppermann et al, J.Immunol. 1993, 151:3785-95
- Schlaf et al, Lab Invest.79:1287-97
- Pollok-Kopp, B. et al., J. Biol. Chem. 2003 278:2190
- Ohl, L. et al., (2004) Immunity21:279-88
- Ritter, U. Et al., (2004) J. Leukoc Biol., 76:472-476
- Soruri, A., Kiafard, Z., Dettmer, C., Riggert, J., Kohl, J., Zwirner, J., (2003), IL-4 down-regulates anaphylatoxin receptors in monocytes and dendritic cells and impairs anaphylatoxin-induced migration in vivo. J. Immunol. 170:3306–3314
- Kiafard, Z., Tschernig, T., Schweyer, S., Bley, A., Neumannd, D., Zwirner, J., (2007), Use of monoclonal antibodies to assess expression of anaphylatoxin receptors in tubular epithelial cells of human, murine and rat kidneys. Immunobiology, 212:129–139
- Werfel, T., Kirchhoff K, Wittmann M, Begemann G, Kapp A, Heidenreich F, Götze O, Zwirner J., (2000) J Immunol., 165:6599-605.
- Zwirner, J., Götze O, Begemann G, Kapp A, Kirchhoff K, Werfel T., (1999), Immunology., 97:166-72
- Luhmann, A.E., et al., 2001, Mol Immunol, 38: 108 (Abstract)
- Godau, J. Et al., (2004), J of Immunol., 173(5): 3437-45
- Soruri, A. et al., (2003), 88: 47-52
- Shushakova, N. et al, (2002), Journal Clin Invest, 110: 1823-30
- Rivera-Nieves J, Ho J, Bamias G, Ivashkina N, Ley K, Oppermann M, Cominelli F. (2006), Gastroenterology. 131 (5):1518-29
- Zahn, S., Zwirner, J., Spengler, H.P., Götze, O. (1997), Eur J Immunol,27(4): 935-40
- Czerny, C.-P., Eichhorn, W. (1989): Characterization of monoclonal and polyclonal antibodies to bovine enteric coronavirus, establishment of an efficient ELISA for antigen detection in feces. Vet.Microbiol.20: 111-122
- Boulanger, D., Green, Smith, T., Czerny, C.-P., Skinner, M.A. (1998): The 131-amino-acid repeat region of the essential 39-kilodalton core protein of fowlpox virus FP9, equivalent to vaccinia virus A4L protein, is non-essential and highly immunogenic. J.Virol.72: 170-179
- Isa, G., Pfister, K., Kaaden, O.-R., Czerny, C.-P. (2002): Development of a monoclonal blocking ELISA for the detection of antibodies against fowlpox virus. J.Vet.Med.B.49: 21-23.
- Czerny, C.-P., Mahnel, H. (1990): Structual und functional analysis of orthopox virus epitopes. J.Gen.Virol., 71: 2341-2352.
- Czerny, C.-P., Johann, S., Hölzle, H., Meyer, H. (1994): Epitope detection in the envelope of intracellular naked orthopox viruses and identification of their encoding genes. Virology200: 764-777.
- Meyer, H., Osterrieder, N., Czerny, C.-P. (1994): Identification of binding sites for neutralizing monoclonal antibodies on the 14 kDa fusion protein of different orthopox virus species. Virology200: 778-783.
- Czerny, C.-P., Waldmann, R., Scheubeck, T. (1997): Identification of three different antigenic sites in parapox viruses. Arch.Virol.142: 807-821.
- Pollok-Kopp B., Hüttenrauch, F., Rethorn, S., Oppermann, M., J. Biol. Chem. (2007) 282:4345
- Huang, C. et al. J. Biol. Chem. (2009) 284:17206
- Hüttenrauch, F. et. al. (2005) J. Biol. Chem. 280:37503
- Liebick M., Schläger C., Oppermann M. (2016) Analysis of Chemokine Receptor Trafficking by Site-Specific Biotinylation. PLOSOne11 (6):e0157502.
Contact
Dipl.-Biol. Christiane Bolli
Licensing Manager Research Materials
E-Mail: cbolli(at)sciencebridge.de
Tel.: +49 551 30724 156
Tags: Antikörper
